17331-16-7

Basic information

• Product Name: N2-DMF-rG
• Synonyms: N2-DMF-rG;methylene]-Guanosine;N-[(Dimethylamino);WDAVDBAMSKZBEN-PZYHSTABSA-N
• CAS NO: 17331-16-7
• Molecular Formula: C₁₃H₁₈N₆O₅
• Molecular Weight: 338.31922
• EINECS: -0
• Mol File: 17331-16-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N2-DMF-rG(CAS DataBase Reference)
• NIST Chemistry Reference: N2-DMF-rG(17331-16-7)
• EPA Substance Registry System: N2-DMF-rG(17331-16-7)

Safety Data

• Hazardous Substances Data: 17331-16-7(Hazardous Substances Data)

Usage

Uses

N2-DMF-rG has a variety of applications across different industries, primarily due to its unique properties and potential impact on RNA structure and function.
Used in Pharmaceutical Industry:
N2-DMF-rG is used as a potential therapeutic agent for regulating gene expression. Its ability to modify RNA structure and function can be harnessed to develop drugs targeting specific genetic disorders or diseases.
Used in Drug Development:
N2-DMF-rG serves as a potential target for drug development, as its unique structure and properties can be exploited to design drugs that modulate RNA function and regulate gene expression.
Used in Nucleic Acid Chemistry:
N2-DMF-rG is utilized in the study of nucleic acid chemistry, where its unique properties can provide insights into the structure, function, and interactions of RNA molecules.
Used in Molecular Biology Research:
N2-DMF-rG is employed in molecular biology research to investigate the role of RNA modifications in gene regulation and to explore the potential of modified nucleosides in controlling gene expression.

Upstream product

• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 118-00-3 G 

Downstream Products

• 160905-73-7 2-N-dimethylaminomethylene-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>guanosine 
• 160905-60-2 2-N-dimethylaminomethylene-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)guanosine 
• 160905-76-0 5'-O-(tert-butyldiphenylsilyl)-2-N-dimethylaminomethylene-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>guanosine 
• 160905-62-4 2-N-dimethylaminomethylene-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-3'-O-(9-phenylxanthen-9-yl)guanosine 
• 160905-71-5 5'-O-(tert-butyldiphenylsilyl)-2-N-dimethylaminomethylene-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-3'-O-(9-phenylxanthen-9-yl)guanosine 
• 1509918-99-3 C₅₉H₈₀N₁₈O₇SSi₂ 
• 1509918-97-1 C₃₉H₅₀N₈O₄Si 
• 1509918-95-9 C₃₉H₄₈N₁₀O₄Si 
• 1509918-90-4 C₂₀H₂₄N₁₀O₃ 
• 1509918-89-1 C₂₁H₂₂N₁₀O₄ 
• 1509918-87-9 C₂₁H₂₃BrN₁₀O₄ 
• 1221574-02-2 C₄₃H₅₇N₇O₅Si 
• 1221574-04-4 C₄₄H₄₆N₈O₁₀ 
• 1221574-03-3 C₅₃H₆₆N₈O₁₀Si 

Relevant articles and documents

Stereoselective and Divergent Aza-Adenosine and Aza-Guanosine Syntheses from Xylofuranose, the Key Fragments of a STING Cyclic Dinucleotide Agonist

The stereoselective and divergent synthesis of two aza-nucleosides is reported. Starting from xylofuranose 9, aza-adenosine 2 was prepared in 13 steps and 7% overall yield, and aza-guanosine 3 was prepared in 13 steps and 7.8% overall yield. Compared to t

METHOD FOR SYNTHESIZING RIBONUCLEIC ACID H-PHOSPHONATE MONOMER, AND OLIGONUCLEOTIDE SYNTHESIS IN WHICH SAID MONOMER IS USED

The present invention pertains to a method for synthesizing a ribonucleic acid H-phosphonate monomer, and a method for performing oligonucleotide synthesis in which said monomer is used. The present invention pertains to a method for manufacturing an inex

CYCLIC DINUCLEOSIDES

Provided herein are compounds of formula Ia: and salts thereof. Also provided are pharmaceutical compositions comprising a compound of formula Ia, processes for preparing compounds of formula Ia, intermediates useful for preparing compounds of formula Ia

MONOMER FOR SYNTHESIS OF RNA, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING RNA

The objective of the present invention is to provide a monomer for RNA synthesis which can be efficiently produced and therefore by which the producing cost of RNA can be remarkably decreased, and a method for efficiently producing the monomer in a small number of steps. In addition, the objective of the present invention is also to provide a method by which RNA can be efficiently produced even when a approximately stoichiometry amount of the monomer for RNA synthesis is used. The monomer for RNA synthesis according to the present invention is represented by the following formula (I) or (I'): wherein R1 is a protective group of the hydroxy group and R2 is an alkyl group or the like.

Synthesis of c-di-GMP analogs with thiourea, urea, carbodiimide, and guanidinium linkages

The first syntheses of neutral thiourea, urea, and carbodiimide analogs, along with two guanidinium analogs, of the bacterial signaling molecule cyclic diguanosine monophosphate (c-di-GMP) are reported. The key intermediate, obtained in nine steps, is a 3

Preparation of fluorinated RNA nucleotide analogs potentially stable to enzymatic hydrolysis in RNA and DNA polymerase assays Dedicated to Dr. Teruo Umemoto on the occasion of receiving the ACS Award for Creative Work in Fluorine Chemistry.

Analogs of ribonucleotides (RNA) stable to enzymatic hydrolysis were prepared and characterized. Computational investigations revealed that this class of compounds with a modified triphosphate exhibits the correct polarity and minimal steric effects compa

SYNTHETIC PGPG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE

The present invention relates to compounds according to Formula I: and salts thereof, wherein R1, R2, R3, R4, and L are as defined herein. Methods for preparing compounds of Formula I are also provided. The present invention further includes methods of treating and preventing bacterial infections, and methods of identifying pGpG-binding domains in bacteria, using the compounds of Formula I.

Caged nucleotides and oligonucleotides and their application

There is disclosed nucleotides and nucleotide analogs having a protecting or “caging” group. There is further disclosed oligonucleotides and oligonucleotides analogs formed having a protecting or “caging” group. There is further disclosed a method for decaging the nucleotides and nucleotide analogs having a protecting or “caging” group and oligonucleotides and oligonucleotide analogs having a caging group.

Design and synthesis of α-carboxy phosphononucleosides

Rhodium catalyzed O-H insertion reactions employing α- diazophosphonate 20 with appropriately protected thymidine, uridine, cytosine, adenosine and guanosine derivatives leads to novel 5′-phosphononucleoside derivatives. Deprotection led to a novel series of phosphono derivatives bearing a carboxylic acid moiety adjacent to the phosphonate group with potential antiviral and/or anticancer activity. The phosphononucleosides bearing an α-carboxylic acid group are envisaged as potential diphosphate mimics. Conversion to mono- and diphosphorylated phosphononucleosides has been effected for evaluation as nucleoside triphosphate mimics. Most of the novel phosphononucleosides proved to be inactive against a variety of DNA and RNA viruses. Only the phosphono AZT derivatives 56-59 showed weak activity against HIV-1 and HIV-2.